Product Description
Mechanisms of Action: VEGFR2 Inhibitor, AhR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Colorectal Cancer
Phase 2: Uterine Cancer|Cervical Cancer|Plasmacytoma|Multiple Myeloma|Skin Cancer|Melanoma|Squamous Cell Carcinoma|Prostate Cancer|Renal Cell Carcinoma|Sarcoma|Head and Neck Cancer|Kidney Cancer|Colorectal Cancer|Gastrointestinal Stromal Tumors|HIV Infections|Mesothelioma|Chronic Myelomonocytic Leukemia|Acute Myelomonocytic Leukemia|Myelodysplastic Syndrome|Astrocytoma|Acute Myeloid Leukemia|Sarcoma, Kaposi|Juvenile Myelomonocytic Leukemia,|Brain Stem Cancer|Anemia, Refractory, with Excess of Blasts|Chronic Myeloid Leukemia|Glioma|Acute Monocytic Leukemia|Adenocarcinoma
Phase 1: Oncology Solid Tumor Unspecified|Peritoneal Cancer|Sarcoma, Kaposi|Fallopian Tube Cancer|Ovarian Cancer|Brain Stem Cancer|Vascular Cancer|Prostate Cancer|Head and Neck Cancer|Inflammatory Breast Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00002226 |
294A | N/A |
Completed |
HIV Infections|Sarcoma, Kaposi |
None |
2019-03-21 |
Treatments |
|
NCT00006247 |
CDR0000068179 | P1 |
Terminated |
Brain Stem Cancer |
2003-07-01 |
2019-03-21 |
Treatments |
|
NCT00005822 |
CWRU5199 | P1 |
Completed |
Inflammatory Breast Cancer |
2002-12-01 |
2025-02-07 |
Primary Endpoints|Treatments |
|
NCT00005642 |
NSC 696819 | P1 |
Completed |
Vascular Cancer |
2002-12-01 |
2019-03-21 |
||
NCT00005647 |
CWRU1399 | P1 |
Completed |
Head and Neck Cancer |
2002-12-01 |
2019-03-21 |
Treatments |
|
NCT00026377 |
11193A | P1 |
Completed |
Prostate Cancer |
2002-03-01 |
2019-03-21 |
Treatments |
|
NCT00006257 |
CDR0000068191 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
None |
2019-03-21 |
Treatments |
|
NCT00006155 |
00-C-0197 | P1 |
Completed |
Peritoneal Cancer|Fallopian Tube Cancer|Ovarian Cancer |
None |
2019-03-21 |
Treatments |
|
NCT00006001 |
NCI-2012-02345 | P2 |
Terminated |
Colorectal Cancer |
2007-02-01 |
2019-03-21 |
Treatments |
|
NCT00006384 |
U01CA062505 | P2 |
Completed |
Kidney Cancer|Renal Cell Carcinoma |
2007-02-01 |
2019-03-21 |
Treatments |
|
NCT00006014 |
NCI-2012-02351 | P2 |
Completed |
Mesothelioma |
2007-02-01 |
2019-03-21 |
Treatments |
|
NCT00004868 |
NABTC-9902 | P2 |
Completed |
Glioma|Astrocytoma|Brain Stem Cancer |
2004-09-15 |
2019-03-21 |
Treatments |
|
NCT00005862 |
CDR0000067893 | P2 |
Completed |
Sarcoma|Gastrointestinal Stromal Tumors |
2004-07-01 |
2019-03-21 |
Treatments |
|
NCT00017316 |
CDR0000068677 | P2 |
Completed |
Melanoma |
2003-09-01 |
2019-03-21 |
Treatments |
|
NCT00006003 |
NCI-2012-02346 | P2 |
Terminated |
Melanoma |
2003-07-01 |
2019-03-21 |
Treatments |
|
NCT00009919 |
NCI-2012-02373 | P2 |
Terminated |
Renal Cell Carcinoma |
2003-06-01 |
2019-03-21 |
Treatments |
|
NCT00005818 |
NCI-2012-02330 | P2 |
Completed |
Colorectal Cancer|Adenocarcinoma |
2003-03-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT00006361 |
CDR0000068232 | P2 |
Completed |
Head and Neck Cancer|Squamous Cell Carcinoma|Melanoma|Skin Cancer |
2003-01-01 |
2019-03-21 |
Treatments |
|
NCT00006013 |
FCCC-00009 | P2 |
Completed |
Multiple Myeloma|Plasmacytoma |
2003-01-01 |
2019-03-21 |
Treatments |
|
NCT00006002 |
UCCRC-10428 | P2 |
Completed |
Prostate Cancer |
2002-09-01 |
2019-03-21 |
||
NCT00005942 |
NCI-2012-02329 | P2 |
Completed |
Juvenile Myelomonocytic Leukemia,|Chronic Myelomonocytic Leukemia|Anemia, Refractory, with Excess of Blasts|Chronic Myeloid Leukemia|Acute Myeloid Leukemia|Acute Myelomonocytic Leukemia|Myelodysplastic Syndrome|Acute Monocytic Leukemia |
2000-12-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT00005042 |
AMC-022 | P2 |
Completed |
Sarcoma, Kaposi |
2000-11-01 |
2019-03-21 |
Treatments |
|
NCT00026260 |
CDR0000069013 | P2 |
Completed |
Uterine Cancer|Cervical Cancer |
None |
2019-03-21 |
Treatments |
|
NCT00023725 |
CDR0000068854 | P2 |
Completed |
Sarcoma |
None |
2019-03-21 |
Treatments |
|
NCT00004252 |
SUGEN-SU5416.031 | P3 |
Completed |
Colorectal Cancer |
2007-09-01 |
2019-03-21 |
Treatments |